EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and
delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and
Pharmacology to Vice-President of Preclinical Research ...
ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA
SALEM, N.H., Aug. 7 /PRNewswire/ -- ALPCO Diagnostics has introduced a Mo u se HMW Adipone c tin EL I SA kit that facilitates the testing process for this biomarker. This ELISA is unique; it is a departure from other methods for determining mouse HMW adiponectin and
was first introd...
Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
EMERYVILLE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it has agreed to sell an aggregate of four million shares of its common stock at a price to the public of $30.50 per share and
$200 million aggregate principal amou...
Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today the appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and
treasurer. Mr. Driscoll will report to Dr. Rahul Singhvi, Novavax's President and
Chief Executive Officer. ...
Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services
ST. LOUIS, Aug. 6 /PRNewswire-FirstCall/ -- Sigma-Aldrich(R) (Nasdaq: SIAL ) today announced the acquisition of cheminformatics company, ChemNavigator(R).com, Incorporated, a provider of leading discovery research informatics software tools used for design, selection and
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
BRISBANE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced results from operations for the second quarter and
six months ended June 30, 2009. InterMune reported a net loss for the second quarter of 2009 of $36.7 million, or $0.81 per shar...
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM ), today reported its financial results for the quarter ended June 30, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO )
Second Quarter Results
Total revenue fo...
PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
ANNAPOLIS, Md., Aug. 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ) a biodefense company developing medical countermeasures against biological and
chemical threats, announced today that its financial results for the second quarter of 2009 will be released on Thursday, Aug...
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
CAMBRIDGE, Massachusetts and
LAUSANNE, Switzerland, August 6 /PRNewswire/
-- Curis, Inc. (NASDAQ: CRIS ), a drug development company focused on
developing proprietary targeted medicines for cancer treatment and
Group (Debiopharm), a group of companies with a focus on the developme...
Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments
UMEA, Sweden, August 6 /PRNewswire/ -- Omnio Healer AB, a pioneer company
developing novel therapies for wound healing and
announced that it has entered into a partnership agreement with Eden
Biodesign. Under the agreement Eden Biodesign will provide process
iCardiac Expands Sales and Marketing Team
Adds Industry Veteran with Over Two Decades of Cardiovascular Core Lab Experience
Rochester, NY (PRWEB) August 6, 2009 -- iCardiac Technologies , Inc., a leader in advanced cardiac safety ECG services and
automated QT analysis, announced that it has expanded its sales ...
ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12
SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX ) today announced that it will hold a conference call on Wednesday, August 12, 2009 at 1:30 p.m. Pacific (4:30 p.m. Eastern) to review financial results for the second quarter and
provide an upda...
AIAG and MichBio Form New Collaborative Partnership
Biosciences Associations join forces to Assist Michigan's Traditional Automotive Manufacturing Base Diversify into Medical Device Manufacturing
Southfield, Mich. (Vocus) August 5, 2009 -- The Automotive Industry Action Group (AIAG) and
CapitalBio Corporation and VigeneTech Inc. Have Announced the Launch of a Fully Integrated Microarray Solution Platform
CARLISLE, Mass., Aug. 5 /PRNewswire/ -- CapitalBio Corporation and
VigeneTech Inc. have announced the launch of a fully integrated microarray solution platform. CapitalBio Corp., a developer and
marketer of diagnostic biochips and
advanced microarray instrument systems, in collaboration with ...
Knighted Adds Industry Pioneer and Entrepreneur to Senior Management Team
WESTCHESTER COUNTY, N.Y., Aug. 5 /PRNewswire/ -- Knighted Computer Systems, Inc. (Knighted), a leading provider of Supply Chain Execution software, today announced that Craig Wilensky, former founder and
board member of InfoLogix, Inc. (Nasdaq: IFLG ) has joined Knighted as E...
Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast
CHICAGO, Aug. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that it will host a conference call and
webcast discussing the Company's 2009 second quarter results on Tuesday, August 11, 2009 at 10:00 a.m. (EDT). Michael T. Fla...
AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
QUEBEC CITY, Aug. 5 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS , TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and
oncology, will announce its second quarter 2009 financial and
operating results before market open on Tuesday, August 11, 2009. The Co...
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on oncology, today reported financial results for the second quarter ended June 30, 2009, and
provided a corporate update.
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
REDWOOD CITY, Calif., Aug 4 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today reported financial results and
business progress for the quarter ended June 30, 2009.
Total revenue increased to $36.6 million in the second quarter of 2009 compared w...
Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
SHANGHAI, Aug. 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd.,
(ChemPartner) a wholly owned subsidiary of ShangPharma Corporation, announced
today that it has moved its drug discovery collaboration with ELARA
Pharmaceuticals to a new level. ChemPartner will provide fully integrated
SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS
SAN DIEGO, CA, August 4, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX ), a company focused on using proprietary taste receptor-based technologies to discover novel flavor ingredients for the food, beverage, and
ingredient supply industries,...
Biotech Hot in July Driven by Positive Drug Data and Acquisitions
SAN FRANCISCO, Aug. 3 /PRNewswire/ -- Biotech was "hot" in July driven by drug data, positive drug sales/earnings and
M&A deals. As a result, the Burrill Biotech Select Index posted a solid monthly gain of 6.5 percent, mirroring the Dow and
Nasdaq, which closed the mon...
SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
SAN DIEGO, CA AND
GENEVA, SWITZERLAND, August 3, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX ), a leading company focused on using proprietary technologies to discover and
develop novel flavor ingredients for the food, beverage, and
ingredient supply indus...
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
STAMFORD, Conn. and
PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today announced entry into an exclusive license and
collaboration agreement to commercialize Intermezzo ((R)) (z...
Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
ROCKVILLE, Md., July 31 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) today announced that it will report its 2009 second quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on Friday, August 7, 2009. The Company will hold an investor conference ...
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
FRAZER, Pa., July 31 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) announced today that Craig C. Phillips has been appointed as Vice President and
General Manager of the Oncology Business Unit. In this role, Phillips will have responsibility for managing all aspect...
PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
ANNAPOLIS, Md., July 31 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and
chemical threats, today announced that, effective July 28, 2009, it has closed on the issuance of 2-year, 10% unsecured ...
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced finalization of the protocol for the Company's Phase II trial of ANA598 in combination with pegylated interferon-alpha and
ribavirin in hepatitis C patients. Allowance o...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its financial results and
Trubion Announces Dates for Second Quarter and First Half 2009 Earnings Conference Call
SEATTLE, July 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN ) today announced that it plans to issue earnings results for its second quarter and
six months ended June 30, 2009, after the close of market on Aug. 6, 2009. The company's earnings conference call w...
SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital
RALEIGH, N.C. , July 30 /PRNewswire/ -- SmartGene, Inc., a provider of novel services for the management and
analysis of genetic data, today announced that it has entered into an agreement under which The Johns Hopkins Hospital will utilize SmartGene's advanced technology and
Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation
TAINAN, Taiwan, July 30 /PRNewswire-Asia/ -- Eli Lilly & Company ("Lilly")
and ScinoPharm Taiwan Ltd. ("ScinoPharm") announced today that they have
reached an amicable resolution of all ongoing patent litigations between the
companies relating to ScinoPharm's manufacture and
sale of gemcit...
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
LAUSANNE, Switzerland and
MEDFORD, Massachussets, July 30 /PRNewswire/ --
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group
of companies with a focus on the development of prescription drugs that
target unmet medical needs, and
MSM Protein Technologies (MSM), a human
"Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan" - Dr. Kailash Sharma, President, Japan Operations, Zydus Cadila
TOKYO, July 30 /PRNewswire/ -- With a business plan to launch 8-10 new
products each year, Nippon Universal Pharmaceutical Co. Ltd., a subsidiary of
the Zydus group, one of India's leading integrated pharma companies & a
global healthcare provider, is looking to give a big boost to its ope...
BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- BP and
Verenium Corporation (Nasdaq: VRNM ) today announced that its 50-50 joint venture company will operate under the name Vercipia Biofuels, and
plan to relocate its corporate headquarters to Florida. Vercipia continues to foc...
BioNeutral Group's CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM 'In Focus' Radio Show Hosted by Dr. Dan Miller
NEWARK, N.J., July 29 /PRNewswire-FirstCall/ -- BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU), a chemical technology-based Life Science company announced today that CEO, Stephen Browand and
Chief Scientist, Dr. Andrew Kielbania will appear on WVOX AM's "In Focus" radio show...
Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) today announced new six month safety and
efficacy results from its fourth Phase II clinical trial using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor an...
NPL and University of Surrey sign £10m deal
The National Physical Laboratory (NPL) and
the University of Surrey have signed an agreement to collaborate on the delivery of a GBP10m programme to translate the results of research into innovation that makes a real-world difference. The collaboration is supported by a GBP4m Knowledge Transfer Ac...
Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
SAN DIEGO, Calif., July 28 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) and
its subsidiary Tissue Repair Company (TRC) today provided an update on the completion of their MATRIX Phase 2b clinical study and
announced plans to provide detailed safety and
RadMD First to Offer CME-Certified Education and Training For Medical Imaging in Clinical Trials
DOYLESTOWN, Pa., July 28 /PRNewswire/ -- RadMD, Inc. ( www.rad-md.net ) has become the first company to offer a broad range of accredited CME courses in the area of medical imaging for pharmaceutical, medical device and
biotech clinical trials.
The comprehensive education a...